Perrigo Company plc (PRGO) Market Cap

Perrigo Company plc (PRGO) has a market capitalization of $1.75B, based on the latest available market data.

Financials updated after earnings reported 2025-12-31.

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 8379
Exchange: New York Stock Exchange
Headquarters: Dublin, , IE
Website: https://www.perrigo.com

Loading company profile...

Expand full investment commentary ▼

📘 PERRIGO PLC (PRGO) — Investment Overview

🧩 Business Model Overview

Perrigo plc (PRGO) is a leading global provider of over-the-counter (OTC) healthcare and wellness products. The company operates as a manufacturer and distributor of consumer self-care products, focusing on affordable, high-quality alternatives to branded medications and personal care solutions. Perrigo’s operations are structured around two main segments: Consumer Self-Care Americas and Consumer Self-Care International, encompassing a diverse portfolio of OTC medicines, nutritional products, and consumer health items available in retail, pharmacy, and e-commerce channels. Through organic development, selective acquisitions, and partnerships, Perrigo aims to provide consumers with both value and trust in its product offerings, positioning itself at the intersection of cost-conscious healthcare and growing self-care awareness.

💰 Revenue Streams & Monetisation Model

Perrigo generates revenue primarily through the manufacture and sale of self-care consumer products. These include OTC pharmaceuticals, infant and adult nutrition, dietary supplements, and personal care items such as skin care and oral hygiene products. The company’s monetisation model leverages large-scale relationships with major retailers, pharmacies, and e-commerce platforms, supplying both store-branded (“private label”) and Perrigo’s own branded products. The firm’s private label business, where it supplies products that retailers sell under their own brands, remains a core revenue driver—especially in segments such as analgesics, allergy relief, lifestyle medications (e.g., smoking cessation), and gastrointestinal care. Perrigo also invests in developing and acquiring established brands to generate incremental value from direct-to-consumer marketing and global distribution. International operations further diversify revenue, tapping into European, Asia-Pacific, and other markets through localized product offerings and partnerships.

🧠 Competitive Advantages & Market Positioning

Perrigo's primary competitive advantage lies in its cost-efficient manufacturing capabilities and expertise in developing generic OTC solutions that compete directly with higher-priced branded products. Its ability to deliver quality, regulatory-compliant goods at lower costs enables retail partners to compete aggressively on price while maintaining margins. The company benefits from longstanding relationships with major retail chains and a reputation for reliability, which grant it significant shelf space and recurring volumes. Perrigo’s broad product portfolio across many therapeutic and wellness categories provides resilience against single-product risks and enhances its negotiating leverage with suppliers and distributors. A notable strategic moat is the company’s focus on store-brand (private label) offerings, which enjoy tailwinds from growing consumer acceptance of private labels and the ongoing drive among retailers to expand their own brands. Regulatory expertise, including a track record of product approvals and compliance across geographies, further bolsters Perrigo's market position relative to potential new entrants.

🚀 Multi-Year Growth Drivers

Several secular and company-specific trends are poised to support Perrigo’s growth over the long term: - **Increasing Self-Care and Preventive Health Awareness:** As consumers take more control over their health and wellness, demand for accessible OTC solutions continues to expand globally. - **Retailer Focus on Private Labels:** Retailer efforts to broaden their private label offerings support Perrigo’s core revenue stream, as stores look to improve margins and foster consumer loyalty. - **Expansion into Adjacent Categories:** The company’s ability to innovate and extend existing platform technologies into adjacent self-care, nutrition, and personal care categories opens new growth avenues. - **International Market Penetration:** Emerging markets and under-penetrated regions offer room for expansion via new product launches, partnerships, and localized brand strategies. - **Strategic M&A:** Perrigo has a history of accretive acquisitions and continues to seek synergistic opportunities, aiming to expand its brand portfolio and geographic footprint. - **E-commerce Channel Growth:** Shifting consumer purchasing patterns toward online channels position Perrigo to capitalize further through direct-to-consumer initiatives and digital partnerships.

⚠ Risk Factors to Monitor

Investors should remain cognizant of the following key risks: - **Generic Product Margin Compression:** The commoditized nature of private label and generic OTC products could compress margins in the event of increased price competition among manufacturers. - **Regulatory Landscape:** As a producer of health-related products, Perrigo is exposed to evolving regulations, recalls, and quality control scrutiny across multiple markets; regulatory delays or compliance failures can impact revenue and reputation. - **Concentration Risk:** Heavy reliance on key retail customers and certain large contracts may expose revenue to renegotiation or channel disruption. - **Supply Chain Vulnerabilities:** Perrigo’s complex manufacturing and distribution networks can be susceptible to supply chain interruptions, raw material cost inflation, or geopolitical trade risks. - **Litigation and Product Liability:** Given the nature of the company’s products, Perrigo is subject to legal risks arising from product recalls, adverse health events, or patent disputes. - **Currency Fluctuations:** As a global company, Perrigo’s financials may be sensitive to changes in exchange rates, particularly given its exposure to European and other international markets.

📊 Valuation & Market View

Perrigo’s valuation typically reflects its predictable cash flow generation and defensive industry profile, balanced against the mature, competitive, and sometimes margin-constrained landscape of generic OTC healthcare. Market sentiment tends to price in stability on the back of recurring revenue from large retail contracts and widespread consumer adoption of private label products. However, growth multiples may remain capped by comparatively modest organic growth rates, ongoing integration risks from acquisitions, and evolving regulatory headwinds. The investment community often evaluates Perrigo on metrics such as enterprise value-to-EBITDA, price-to-earnings, and free cash flow yield relative to peers in the consumer health and generic pharmaceutical segments. Long-term growth potential and downside protection are key factors analysts consider, with a keen eye on execution in new product launches, international expansion, and margin management.

🔍 Investment Takeaway

Perrigo plc stands as a significant player in the OTC healthcare and consumer self-care market, underpinned by its strengths in cost-efficient manufacturing, wide distribution, and private label leadership. Its diversified product mix and global reach provide a level of resilience uncommon in the sector, helping buffer against isolated market or product shocks. The company’s growth prospects are fueled by enduring consumer and retail trends toward self-care and private-label products, supported by strategic moves into adjacent categories and international markets. However, investors must weigh the company’s defensive attributes against potential headwinds such as intensifying price competition, regulatory unpredictability, and reliance on a handful of major retail partners. For a long-term, risk-tolerant investor seeking exposure to the stable but evolving consumer health sector, Perrigo offers a solid, cash-generative proposition with the potential for moderate growth and further operational improvements. Continuous monitoring of regulatory developments, competitive dynamics, and execution on growth strategies remains essential for a sustained investment thesis.

⚠ AI-generated — informational only. Validate using filings before investing.

📊 Perrigo Company plc (PRGO) — AI Scoring Summary

📊 AI Stock Rating — Summary

For Q4 2025, PRGO reported revenue of $1.11 billion and a net income loss of $1.42 billion, translating to an EPS of -$10.23. Despite negative net income, the company generated a free cash flow of $148.6 million, supported by operating cash flow of $175.4 million and capital expenditure of $26.8 million. The balance sheet shows a solid net cash position, with total assets at $8.54 billion against liabilities of $5.6 billion, resulting in a net debt of -$495 million. Quarterly dividends were maintained at $0.29 per share, with a 1-year price target consensus at $21.5. PRGO shows resilience in cash generation amid substantial losses due to likely one-off expenses or adjustments. The company has no recent debt or equity financing, indicating a stable capital structure, though insufficient profitability impacts valuation attractiveness. Analyst sentiment remains cautious with targeted stock prices suggesting modest upside potential. Continuing dividends underscore a commitment to shareholder returns despite financial challenges.

AI Score Breakdown

Revenue Growth — Score: 6/10

Revenues for the quarter reached $1.11 billion, indicating stable core business performance, though growth catalysts are unclear.

Profitability — Score: 3/10

Reported a substantial net loss of $1.42 billion with negative EPS, impacting operational efficiency and highlighting profitability issues.

Cash Flow Quality — Score: 7/10

Solid free cash flow of $148.6 million, strong operating cash, and consistent dividend payouts highlight good liquidity management.

Leverage & Balance Sheet — Score: 8/10

A strong net cash position with total equity of $2.94 billion provides financial stability and resilience against liabilities.

Shareholder Returns — Score: 6/10

Consistent dividend payments demonstrate a focus on returning value to shareholders amid earnings challenges.

Analyst Sentiment & Valuation — Score: 4/10

Valuation metrics suggest limited upside, with analyst targets indicating cautious market expectations given current financials.

⚠ AI-generated — informational only, not financial advice.

SEC Filings

Related Companies in Healthcare

SRPT logo

SAREPTA THERAPEUTICS INC (SRPT)

Healthcare

$1.76B

ELVN logo

ENLIVEN THERAPEUTICS INC (ELVN)

Healthcare

$1.76B

ZYME logo

ZYMEWORKS INC (ZYME)

Healthcare

$1.74B

AGIO logo

AGIOS PHARMACEUTICALS INC (AGIO)

Healthcare

$1.77B

TYRA logo

TYRA BIOSCIENCES INC (TYRA)

Healthcare

$1.78B

RLAY logo

RELAY THERAPEUTICS INC (RLAY)

Healthcare

$1.78B